CHEPLAPHARM Arzneimittel GmbH
CHEPLAPHARM Arzneimittel GmbH, a prominent player in the pharmaceutical industry, is headquartered in Greifswald, Germany. Founded in 1986, the company has established itself as a leader in the development, production, and distribution of high-quality generic and specialty pharmaceuticals. With a strong presence across Europe and expanding operations in various international markets, CHEPLAPHARM focuses on therapeutic areas such as oncology, cardiology, and neurology. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to the evolving needs of healthcare providers and patients. Notable achievements include strategic partnerships and a robust pipeline of generics that enhance patient access to essential medications. CHEPLAPHARM's dedication to excellence positions it as a trusted name in the pharmaceutical landscape, continually striving to improve health outcomes worldwide.
DitchCarbon Score
How does CHEPLAPHARM Arzneimittel GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CHEPLAPHARM Arzneimittel GmbH's score of 15 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
CHEPLAPHARM Arzneimittel GmbH's reported carbon emissions
In 2023, CHEPLAPHARM Arzneimittel GmbH reported carbon emissions of approximately 130,900 kg CO2e, comprising 111,000 kg CO2e from Scope 1 emissions, which include process emissions, and 16,000 kg CO2e from Scope 2 emissions related to purchased heat. This represents a slight increase in Scope 1 emissions compared to 2022, where they were about 111,000 kg CO2e, while Scope 2 emissions decreased from 198,000 kg CO2e in 2022. In 2022, the company achieved a total of approximately 182,000 kg CO2e in combined Scope 1 and 2 emissions. The breakdown for that year included 111,000 kg CO2e from Scope 1 and 198,000 kg CO2e from Scope 2. Despite these figures, CHEPLAPHARM has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of formal climate pledges or science-based targets indicates a potential area for improvement in their sustainability strategy. Overall, while CHEPLAPHARM has made strides in tracking their emissions, further commitments and reduction strategies would enhance their climate responsibility and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | - | 000,000 |
| Scope 2 | 323,000 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CHEPLAPHARM Arzneimittel GmbH is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
